The famend well being and wellness platform, Hims & Hers Well being, Inc. HIMS, operates on the intersection of shopper well being, wellness and digital healthcare, mixing telemedicine, personalised therapies and direct-to-consumer wellness merchandise right into a unified mannequin. Its platform supplies entry to licensed healthcare professionals and personalised care plans for power and life-style situations similar to sexual well being, hair loss, dermatology, psychological well being and weight administration. This mannequin integrates telehealth consultations, pharmacy success and recurring subscriptions — making a recurring income stream whereas enabling precision-based, individualized care.
The corporate’s enterprise mannequin overlaps in shopper well being and wellness stems from its emphasis on accessibility and personalization. Hims & Hers’ development technique expands past digital prescriptions into holistic care, supported by its acquisition of Trybe Labs for lab testing and MedisourceRx for compounding capabilities. This vertical integration enhances its precision well being infrastructure. The current appointment of AI professional Mo Elshenawy as chief know-how officer (CTO) and an $870 million convertible word providing underscore its ambition to scale AI-driven diagnostics and coverings globally.
Current class launches additional broaden its shopper well being portfolio. The introduction of a males’s oral testosterone line and ladies’s menopause and perimenopause specialty marks main entries into hormonal well being, complementing the corporate’s increasing weight reduction choices. Coupled with its ZAVA acquisition in Europe and deliberate 2026 growth to Canada, Hims & Hers is evolving into a worldwide, technology-enabled shopper wellness supplier that mixes medical-grade remedy entry with personalised life-style care.
GDRX & MED’s Client Well being and Wellness Platforms
GoodRx Holdings, Inc. GDRX operates on the intersection of healthcare, know-how and shopper wellness, connecting sufferers, pharmacies and drug producers via its digital financial savings platform. In October, GDRX launched GoodRx for Hair Loss, a males’s subscription providing digital consultations and reasonably priced therapies, and RxSmartSaver, a pharmacy-counter program increasing financial savings on model medication. Its collaboration with Amgen on Repatha additional emphasizes GoodRx’s position in increasing reasonably priced entry and strengthening its place within the shopper well being and wellness ecosystem.
Medifast, Inc. MED is shifting from weight reduction to metabolic well being, introducing Metabolic Synchronization, which resets metabolism to cut back visceral fats and protect lean mass. Supported by analysis on its Optimum Weight 5 & 1 Plan, displaying 98% lean mass preservation, Medifast leverages medical science, personalised teaching and behavioral help to boost metabolic outcomes. Medifast’s evidence-based, coach-guided method aligns it with the broader shopper well being and wellness motion targeted on longevity and vitality.
HIMS’ Value Efficiency, Valuation and Estimates
Shares of Hims & Hers have gained 82.2% 12 months so far, outperforming the business’s development of 24.2%.
Picture Supply: Zacks Funding Analysis
HIMS’ ahead 12-month P/S of three.7X is decrease than the business’s common of 5.6X, however is greater than its three-year median of two.5X. It carries a Worth Rating of D.
Picture Supply: Zacks Funding Analysis
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 118.5% enchancment from 2024.
Picture Supply: Zacks Funding Analysis
Hims & Hers presently carries a Zacks Rank #3 (Maintain).
You possibly can see the entire listing of as we speak’s Zacks #1 Rank (Sturdy Purchase) shares right here.
MEDIFAST INC (MED) : Free Inventory Evaluation Report
GoodRx Holdings, Inc. (GDRX) : Free Inventory Evaluation Report
Hims & Hers Well being, Inc. (HIMS) : Free Inventory Evaluation Report
This text initially revealed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
